Agios Pharmaceuticals, Inc., the leading biopharmaceutical company focused on discovering and developing novel drugs in the fields of cancer metabolism and rare metabolic genetic diseases, today announced that Katharine Yen, Ph.D., director, biology, will present insights into the company’s lead isocitrate dehydrogenase (IDH) program at the Tumor Metabolism Keystone Symposia being held February 24-March 1, 2013 in Keystone, Colo.
